Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;21(8):547–552. doi: 10.1002/clc.4960210804

A review of the amyloidoses that infiltrate the heart

ROBERT E MCCARTHY, III III 1, EDWARD K Kasper 1,✉
PMCID: PMC6655639  PMID: 9702380

Abstract

Primary amyloidosis, systemic senile amyloidosis, isolated atrial amyloidosis, and transthyretin isoleucine 122 amyloidosis frequently involve the heart. Amyloid fibrils infiltrate the myocardium, impairing ventricular contraction and relaxation. The clinical manifestations of cardiac infiltration in these disorders are protean, though congestive heart failure and arrhythmias are most common. Treatment of cardiac amyloidosis is directed at the underlying cause and at relief of symptoms. Heart transplantation is not a viable treatment option for patients with primary amyloidosis; its role in the other amyloidoses has not been established. The prognosis of patients with cardiac amyloidosis varies and is largely determined by the underlying disorder responsible for amyloid infiltration.

Keywords: amyloidosis, infiltrative cardiomyopathy, heart failure, myocardial hypertrophy, heart transplantation

Full Text

The Full Text of this article is available as a PDF (724.7 KB).

References

  • 1. Glenner GG: Amyloid deposits and amyloidosis. The β‐fibrilloses. N Engl J Med 1980; 302: 1283–1290; 1333–1341 [DOI] [PubMed] [Google Scholar]
  • 2. Stevens FJ, Myatt EA, Chang CH, Westholm FA. Eulitz M, Weiss DT, Murphy C, Solomon A, Schiffer M: A molecular model for self‐assembly of amyloid fibrils: Immunoglobulin light chains. Biochemistry 1995; 34: 10697–10702 [DOI] [PubMed] [Google Scholar]
  • 3. Smith RR, Hutchins GM: Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol 1979; 44: 413–417 [DOI] [PubMed] [Google Scholar]
  • 4. Ridolfi BL, Bulkley BH, Hutchins GM: The conduction system in cardiac amyloidosis: Clinical and pathologic features of 23 patients. Am J Med 1977; 62: 677–686 [DOI] [PubMed] [Google Scholar]
  • 5. Garcia R, Saeed SM: Amyloidosis: Cardiovascular manifestations in five illustrative cases. Arch Intern Med 1968; 121: 259–266 [DOI] [PubMed] [Google Scholar]
  • 6. Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995: 32: 45–59 [PubMed] [Google Scholar]
  • 7. Kyle RA, Greipp PR: Amyloidosis: Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665–683 [PubMed] [Google Scholar]
  • 8. Kyle RA, Greipp PR, O'Fallon WM : Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68: 220–224 [PubMed] [Google Scholar]
  • 9. Patel AR, Dubrey SW, Mendes LA, Skinner M, Cupples A, Falk RH, Davidoff R: Right ventricular dilation in primary amyloidosis: An independent predictor of survival. Am J Cardiol 1997; 80: 486–492 [DOI] [PubMed] [Google Scholar]
  • 10. Cueto‐Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, Offord KP, Greipp PR, Edwards WD, Tajik AJ: Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement. J Am Coll Cardiol 1985; 6: 737–743 [DOI] [PubMed] [Google Scholar]
  • 11. Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA, Bailey KR, Seward JB, Tajik AJ: Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. Circulation 1991; 82: 808–816 [DOI] [PubMed] [Google Scholar]
  • 12. Tei C, Dujardin KS, Hodge DO, Kyle RA, Tajik AJ, Seward JB: Doppler Index combining systolic and diastolic myocardial performance: Clinical value in cardiac amyloidosis. J Am Coll Cardiol 1996; 28: 658–664 [DOI] [PubMed] [Google Scholar]
  • 13. Cornwell GG, Murcoch WL, Kyle RA, Westermark P, Pitkanen P: Frequency and distribution of senile cardiovascular amyloid: A clinicopathologic correlation. Am J Med 1983; 75: 618–623 [DOI] [PubMed] [Google Scholar]
  • 14. Johansson B, Wemstedt C, Westermark P: Atrial natriuretic peptide deposited as atrial amyloid fibrils. Biochem Biophys Res Commun 1987; 148: 1087–1092 [DOI] [PubMed] [Google Scholar]
  • 15. Soyka J: Veber amyloide degeneration. Prog Med Wschr 1876; 1: 165. [Google Scholar]; Cited in Pomerance A: Senile cardiac amyloidosis. Br Heart J 1965; 27: 711–718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. King LS: Atypical amyloid disease with observations on a new silver stain for amyloid. Am J Pathol 1948; 24: 1095–1116 [PMC free article] [PubMed] [Google Scholar]
  • 17. Lie JT, Hammond PI: Pathology of the senescent heart: Anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc 1988; 63: 552–564 [DOI] [PubMed] [Google Scholar]
  • 18. Pitkanen P, Westermark P, Cornwell GG: Senile systemic amyloidosis. Am J Pathol 1984; 117: 391–399 [PMC free article] [PubMed] [Google Scholar]
  • 19. Westermark P, Sletten K, Johansson B, Cornwell GG: Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Nat Acad Sci USA 1990; 87: 2843–2845 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Smith TJ, Kyle RA, Lie JT: Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 1984; 59: 547–555 [DOI] [PubMed] [Google Scholar]
  • 21. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, Thibodeau SN: The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996; 101: 395–400 [DOI] [PubMed] [Google Scholar]
  • 22. Jacobson DR, Gorevic PD, Buxbaum JN: A homozygous transthyretin variant associated with senile systemic amyloidosis: Evidence for a late‐onset disease of genetic etiology. Am J Human Genet 1990; 47: 127–136 [PMC free article] [PubMed] [Google Scholar]
  • 23. Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN: Revised transthyretin Ile 122 allele frequency in African‐Americans. Hum Genet 1996; 98: 236–238 [DOI] [PubMed] [Google Scholar]
  • 24. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN: Variant‐sequence transthyretin (isoleucine 122) in late‐onset cardiac amyloidosis in Black Americans. N Engl J Med 1997; 336: 466–473 [DOI] [PubMed] [Google Scholar]
  • 25. Siquiera‐Filho AG. Cunha CL, Tajik AJ, Seward JV. Schottenberg TT, Guillani ER: M‐mode and two‐dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981; 63: 188–196 [DOI] [PubMed] [Google Scholar]
  • 26. Falk RH. Plehn JF. Deering T, Schick EC, Boinay P, Rubinow A, Skinner M, Cohen AS: Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987; 59: 418–422 [DOI] [PubMed] [Google Scholar]
  • 27. Larsen RM: A pathological study of primary myocardial amyloidosis. Am J Pathol 1930; 6: 147–160 [PMC free article] [PubMed] [Google Scholar]
  • 28. Lindsay S: The heart in primary systemic amyloidosis. Am Heart J 1946; 32: 419–437 [DOI] [PubMed] [Google Scholar]
  • 29. Carroll JD, Gaasch WH, McAdam KP: Amyloid cardiomyopathy: Characterization by a distinctive voltage/mass relation. Am J Cardiol 1982; 49: 9–13 [DOI] [PubMed] [Google Scholar]
  • 30. Duston MA, Skinner M, Shirahama T, Cohen AS: Diagnosis of amyloidosis by abdominal fat aspiration: Analysis of four years' experience. Am J Med 1987; 82: 412–414 [DOI] [PubMed] [Google Scholar]
  • 31. Schroeder JS, Billingham ME, Rider AK: Cardiac amyloidosis: Diagnosis by transvenous endomyocardial biopsy. Am J Med 1975; 59: 269–273 [DOI] [PubMed] [Google Scholar]
  • 32. Pellikka PA, Holmes DR, Edwards WD, Nishimura RA, Tajik AJ, Kyle RA: Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med 1988; 148: 662–666 [PubMed] [Google Scholar]
  • 33. Gertz MA, Kyle RA, Edwards WD: Recognition of congestive heart failure due to senile cardiac amyloidosis. Biomed Pharmacother 1989; 43: 101–106 [DOI] [PubMed] [Google Scholar]
  • 34. Hosenpud JD, DeMarco T, Frazier OH, Griffith BP, Uretsky BF, Menkis AH, O'Connell JB, Olivari MT, Valantine HA: Progression of systemic disease and reduced long‐term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation 1991; 84 (suppl III): 338–343 [PubMed] [Google Scholar]
  • 35. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207 [DOI] [PubMed] [Google Scholar]
  • 36. Cassidy JT: Cardiac amyloidosis: Two cases with digitalis sensitivity. Ann Intern Med 1961; 55: 989–994 [DOI] [PubMed] [Google Scholar]
  • 37. James TN: Pathology of the cardiac conduction system in amyloidosis. Ann Intern Med 1966; 65: 28–36 [DOI] [PubMed] [Google Scholar]
  • 38. Buja LM, Khoi NB, Roberts WC: Clinically significanl cardiac amyloidosis: Clinicopathologic findings in 15 patients. Am J Cardiol 1970; 26: 394–405 [DOI] [PubMed] [Google Scholar]
  • 39. Roberts WC, Waller BF: Cardiac amyloidosis causing cardiac dysfunction: Analysis of 54 necropsy patients. Am J Cardiol 1983; 52: 137–146 [DOI] [PubMed] [Google Scholar]
  • 40. Brandt K, Cathcart ES, Cohen AS: A clinical analysis of the course and prognosis of forty‐two patients with amyloidosis. Am J Med 1968; 44: 955–969 [DOI] [PubMed] [Google Scholar]
  • 41. Rubinow A, Skinner M, Cohen AS: Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63: 1285–1288 [DOI] [PubMed] [Google Scholar]
  • 42. Hodkinson HM, Pomerance A: The clinical significance of senile cardiac amyloidosis: A prospective clinico‐pathological study. Quarterly J Med 1977; 46: 381–387 [PubMed] [Google Scholar]
  • 43. Smith TW: Digitalis mechanisms of action and clinical use. N Engl J Med 1988; 318: 358–365 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES